[High-dose chemotherapy of metastatic breast carcinoma].
OBJECTIVE
To evaluate efficacy and toxicity of high-dose chemotherapy (HDCT) in metastatic breast cancer (MBC) MATERIALS AND METHODS: A literature search from January 1988 until July 1998 about the treatment of metastatic breast cancer with high dose chemotherapy was conducted.


RESULTS
After HDCT the overall response rate was about 80%, with 50% of complete remissions. The median survival was > 18 months. Approximately 20% of the patients experienced long-term progression-free survival.


CONCLUSIONS
Although current results appear promising, randomised trials are required to determine the role of HDCT in the treatment of patients with MBC.
Tartarone
A
A
Divisione di Oncologia, Casa Sollievo della Sofferenza, IRCCS, S. Giovanni Rotondo, Italia.
Aieta
M
M
Morritti
M G
MG
Palomba
G
G
Romano
M P
MP
Lelli
G
G
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans
D000970:Antineoplastic Agents
Chemioterapia ad alte dosi del carcinoma metastatico della mammella.